. 2018 Oct 5;9(78):34765–34771. doi: 10.18632/oncotarget.26192
Copyright: © 2018 Hata et al.
This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
Figure 2. Time to treatment failure of osimertinib.
